Loading
Life sciences · Journal article
Acs Applied Nano Materials · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Breast cancer remains a major global health concern, highlighting the need for advanced drug delivery strategies that can improve therapeutic efficacy while minimizing systemic toxicity. Although several reviews have discussed polymeric nanocarriers for breast cancer therapy, many have primarily focused on specific polymeric platforms, individual stimuli-responsive mechanisms, or conventional formulation strategies, with limited integration of emerging biomimetic and biologically inspired approaches and the most recent advances in the field. This review addresses this gap by providing a comprehensive and critical assessment of recent developments in polymeric nanocarriers for breast cancer drug delivery, with particular emphasis on pH-responsive and other stimuli-sensitive systems, chemical and surface modifications, advanced formulation strategies, and emerging polymer−lipid hybrid, biomimetic, and extracellular vesicle-inspired nanocarriers. The review further highlights how these approaches can improve drug loading, controlled release, tumor-specific accumulation, cellular uptake, and therapeutic efficacy while reducing systemic toxicity. In addition, current challenges related to stability, reproducibility, scalability, safety, and clinical translation are critically discussed to identify key directions for future development. By integrating conventional polymeric strategies with emerging biomimetic and multifunctional platforms, this review provides a contemporary framework for understanding the evolution of polymeric nanocarriers and identifying opportunities for more precise and clinically translatable breast cancer therapy.